glp-1 obesity drug news october 2025 ISPOR 2025: Exploring reasons for discontinuation Alarming rise in weight loss

Quantitation of bias Bias between cAMP, -arrestin-1, and -arrestin-2 responses was determined using a modified operational model of agonism

These important negative data support the hypothesis that even in a weight-reduced state from peak obesity, the DVC GLP-1R and amylin receptors theoretically remain as continued viable drug targets for sustaining weight loss

Of patients taking GLP-1, 8.9% developed NAION compared to 1.8% of patients taking other medications

Am J Physiol-Regul Integr Comp Physiol (2016) 310:R88595

These effects limited EMT and invasive behavior (Zhao et al., 2014)

The extracellular N-terminus contains key regions involved in ligand recognition and binding